Home Stock

Stock Research: Divi's Laboratories

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Divi's Laboratories

NSI:DIVISLAB INE361B01024
73
  • Value
    7
  • Growth
    83
  • Safety
    Safety
    85
  • Combined
    61
  • Sentiment
    56
  • 360° View
    360° View
    73
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Divi's Laboratories Limited is an India-based company engaged in pharmaceutical ingredients, intermediates, and nutraceutical ingredients with a focus on exports and custom synthesis. Its main businesses include manufacturing active pharmaceutical ingredients (APIs) and intermediates, and providing contract manufacturing services for global innovator companies across various therapeutic areas. The company operates in India and has subsidiaries in the USA and Europe. In the last fiscal year, the company had a market cap of $21095 million, profits of $587 million, revenue of $1095 million, and 18300 employees.

more

ANALYSIS: With an Obermatt 360° View of 28 (better than 28% compared with alternatives), overall professional sentiment and financial characteristics for the stock Divi's Laboratories are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Divi's Laboratories. The consolidated Growth Rank has a good rank of 51, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 51% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 86 which means that the company has a financing structure that is safer than 86% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 7 which means that the share price of Divi's Laboratories is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 93% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 26, which means that professional investors are more pessimistic about the stock than for 74% of alternative investment opportunities. ...read more

more
Strongest Rank Price vs. Sales (P/S)
Weakest Rank Leverage
Country India
Industry Life Sciences Tools & Services
Size Large
Website divislabs.com
Index
Divi's Laboratories stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 26-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
7 5 11 15
Growth
83 81 43 81
Safety
Safety
85 99 100 100
Sentiment
56 67 49 6
360° View
360° View
73 19 59 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
21 7 1 27
Opinions Change
49 94 50 17
Pro Holdings
n/a 81 73 40
Market Pulse
100 60 64 55
Sentiment
56 67 49 6
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
7 5 11 15
Growth
83 81 43 81
Safety Safety
85 99 100 100
Combined
61 37 55 87
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
1 1 5 3
Price vs. Earnings (P/E)
8 5 12 22
Price vs. Book (P/B)
10 14 28 20
Dividend Yield
47 31 39 44
Value
7 5 11 15
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
77 84 74 76
Profit Growth
75 74 34 63
Capital Growth
83 14 50 70
Stock Returns
43 99 37 65
Growth
83 81 43 81
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
97 100 96 100
Refinancing
22 42 50 40
Liquidity
91 100 98 100
Safety Safety
85 99 100 100

Similar Stocks

Discover high‑ranked alternatives to Divi's Laboratories and broaden your portfolio horizons.

Tech Mahindra

NSI:TECHM
Country: India
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Petronet LNG

NSI:PETRONET
Country: India
Industry: Oil & Gas Transportation
Size: Large
Full Stock Analysis

Apollo Tyres

NSI:APOLLOTYRE
Country: India
Industry: Tires & Rubber
Size: Large
Full Stock Analysis

Aurobindo Pharma

NSI:AUROPHARMA
Country: India
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews